Achillion: Corporate Presentation (Achillion) - Jul 4, 2014 - "ACH-3102: Phase 1 Activity Second-generation NS5A Inhibitor"; "Robust activity against genotype 1a and 1b HCV in Phase 1"; "Single dose as low as 25 mg achieved greater than 4.5 log10 reduction in GT 1b HCV"; "Well tolerated with prolonged antiviral activity observed"; "Consistent antiviral effect despite presence of baseline NS5A mutations"
P1 data • Hepatitis C Virus
|